Situation
- Global pharma company faced with shrinking R&D budget
- Poor track record in progressing in-house innovation through to market:
- High failure rate
- Excessively costly
Actions
- Major program working with leadership teams of Research and Development to examine the issues resulting at the R to D interface
- Re-designed R to D interface to enable expedited Proof of Concept
- New processes, new objectives, new governance responsibilities and mechanisms
- Design and implementation planning
Results
- New interface enabled ‘Fast fail’ – earlier, better informed decision making and saving significant costs associated with late stage failures
- Research accountability extended to PoC
- Improved flow of quality candidates from Research
- Improved knowledge sharing between Development, Preclinical and Research